False-Positive Human Immunodeficiency Virus Nucleic Acid Amplification Test After Chimeric Antigen Receptor T-Cell Therapy With Ciltacabtagene Autoleucel-Reference-Cited by-同舟云学术

False-Positive Human Immunodeficiency Virus Nucleic Acid Amplification Test After Chimeric Antigen Receptor T-Cell Therapy With Ciltacabtagene Autoleucel

Published:2023-12-11 Issue:1 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Keri Vishakh C¹^ORCID,Topulli Mary Vito²,Deol Abhinav²,Uberti Joseph²,Salimnia Hossein³,Chandrasekar Pranatharthi H¹²

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Wayne State University , Detroit, Michigan , USA

2. Karmanos Cancer Center, Wayne State University , Detroit, Michigan , USA

3. Department of Laboratory services, Detroit Medical Center , Detroit, Michigan , USA

Abstract

Abstract Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel therapeutic option for hematologic malignancies. Human immunodeficiency virus (HIV) nucleic acid amplification tests (NAATs) amplifying 5′ long terminal repeat and gag genes cross-react with lentiviral vector-based CAR T-cell products. Cross-reactivity between CAR T-cell products and HIV NAATs may lead to false-positive test results.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofad633/54253118/ofad633.pdf

Reference12 articles.

1. CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions;Gill;Am Soc Clin Oncol Educ Book,2021

2. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma;Yang;Cancer Lett,2023

3. CAR-T cell potency: from structural elements to vector backbone components;Mazinani;Biomarker Res,2022

4. CARVYKTI (ciltacabtagene autoleucel) package insert;US Food and Drug Administration

5. False-positive human immunodeficiency virus test results in patients receiving lentivirus-based chimeric antigen receptor T-cell therapy: case report, review of the literature, and proposed recommendations;Villalba;J Infect Dis,2022